Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$1.98M Sell
5,476
-4,482
-45% -$1.53M 0.4% 43
2026
Q1
$3.5M Sell
9,958
-91
-0.9% -$32.4K 0.76% 35
2025
Q4
$3.29M Sell
10,049
-98
-1% -$31.1K 0.66% 37
2025
Q3
$2.86M Buy
10,147
+109
+1% +$31.6K 0.59% 37
2025
Q2
$2.8M Sell
10,038
-97
-1% -$27.5K 0.59% 38
2025
Q1
$3.16M Buy
10,135
+190
+2% +$56.1K 0.7% 37
2024
Q4
$2.59M Sell
9,945
-44
-0.4% -$13.1K 0.54% 38
2024
Q3
$3.22M Sell
9,989
-76
-0.8% -$24.9K 0.7% 37
2024
Q2
$3.14M Buy
10,065
+399
+4% +$117K 0.72% 35
2024
Q1
$2.75M Buy
9,666
+228
+2% +$66.7K 0.65% 37
2023
Q4
$2.72M Sell
9,438
-3,043
-24% -$829K 0.7% 37
2023
Q3
$3.35M Sell
12,481
-505
-4% -$126K 0.97% 32
2023
Q2
$2.88M Sell
12,986
-381
-3% -$88.4K 0.76% 37
2023
Q1
$3.23M Buy
13,367
+878
+7% +$216K 0.87% 36
2022
Q4
$3.28M Buy
12,489
+1,251
+11% +$335K 0.95% 36
2022
Q3
$2.53M Sell
11,238
-588
-5% -$143K 0.75% 42
2022
Q2
$2.88M Buy
11,826
+10,776
+1,026% +$2.64M 0.9% 36
2022
Q1
$254K Hold
1,050
0.07% 64
2021
Q4
$236K Hold
1,050
0.05% 79
2021
Q3
$223K Sell
1,050
-287
-21% -$66.1K 0.05% 83
2021
Q2
$326K Sell
1,337
-120
-8% -$29.5K 0.08% 64
2021
Q1
$363K Sell
1,457
-608
-29% -$145K 0.1% 63
2020
Q4
$475K Buy
2,065
+946
+85% +$218K 0.14% 54
2020
Q3
$284K Hold
1,119
0.1% 53
2020
Q2
$264K Buy
+1,119
New +$255K 0.1% 59
2020
Q1
Sell
-985
Closed -$237K 65
2019
Q4
$237K Sell
985
-165
-14% -$36.4K 0.07% 68
2019
Q3
$223K Hold
1,150
0.08% 67
2019
Q2
$212K Sell
1,150
-115
-9% -$20.6K 0.08% 56
2019
Q1
$240K Buy
1,265
+200
+19% +$38.2K 0.09% 55
2018
Q4
$207K Hold
1,065
0.09% 54
2018
Q3
$221K Buy
+1,065
New +$210K 0.09% 59
2018
Q1
Sell
-1,489
Closed -$259K 69
2017
Q4
$259K Buy
+1,489
New +$264K 0.08% 67

Other funds holding AMGN

Fulcrum Capital's AMGN Position: Q2 2026 in Review

Fulcrum Capital reduced its Amgen (AMGN) stake by 45% in Q2 2026, selling an estimated $1.53M and leaving 5,476 shares worth $1.98M. The position accounts for 0.4% of the portfolio, ranked #43.

Fulcrum Capital first reported a position in AMGN in Q4 2017 and has held it in 32 quarters since. The position peaked at $3.5M in Q1 2026. 1,334 funds tracked by Wall St. Rank hold AMGN as of Q2 2026.

  • Fulcrum Capital held 5,476 shares of Amgen worth $1.98M as of Q2 2026.
  • Fulcrum Capital sold 4,482 Amgen shares in Q2 2026, an estimated $1.53M.
  • Amgen made up 0.4% of Fulcrum Capital's portfolio in Q2 2026, its #43 holding.
  • Fulcrum Capital first reported a position in Amgen in Q4 2017 and has held it in 32 quarters since.
  • Fulcrum Capital's Amgen position peaked at $3.5M in Q1 2026.
  • 1,334 funds tracked by Wall St. Rank held Amgen as of Q2 2026.

Based on Fulcrum Capital's 13F filing for Q2 2026, filed 21 Jul 2026.